Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment

Cytotoxic T lymphocytes and NK cells play an important role in eliminating malignant tumor cells and the number and activity of tumor-infiltrating T cells represent a good marker for tumor prognosis. Based on these findings, immunotherapy, e.g., checkpoint blockade, has received considerable attention during the last couple of years. However, for the majority of patients, immune control of their tumors is gray theory as malignant cells use effective mechanisms to outsmart the immune system. Increasing evidence suggests that changes in tumor metabolism not only ensure an effective energy supply and generation of building blocks for tumor growth but also contribute to inhibition of the antitumor response. Immunosuppression in the tumor microenvironment is often based on the mutual metabolic requirements of immune cells and tumor cells. Cytotoxic T and NK cell activation leads to an increased demand for glucose and amino acids, a well-known feature shown by tumor cells. These close metabolic interdependencies result in metabolic competition, limiting the proliferation, and effector functions of tumor-specific immune cells. Moreover, not only nutrient restriction but also tumor-driven shifts in metabolite abundance and accumulation of metabolic waste products (e.g., lactate) lead to local immunosuppression, thereby facilitating tumor progression and metastasis. In this review, we describe the metabolic interplay between immune cells and tumor cells and discuss tumor cell metabolism as a target structure for cancer therapy. Metabolic (re)education of tumor cells is not only an approach to kill tumor cells directly but could overcome metabolic immunosuppression in the tumor microenvironment and thereby facilitate immunotherapy.

[1]  W. Gronwald,et al.  Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model , 2013, International journal of cancer.

[2]  J. Mitchell,et al.  Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  P. Schlag,et al.  Plasma glutamate concentration and lymphocyte activity , 2004, Journal of Cancer Research and Clinical Oncology.

[4]  Abhishek K. Jha,et al.  Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. , 2015, Immunity.

[5]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[6]  J. Gribben,et al.  Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. , 2015, Blood.

[7]  Hans-Georg Rammensee,et al.  IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism , 2008, Cancer Immunology, Immunotherapy.

[8]  Jennifer B Dennison,et al.  Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models , 2011, Molecular Cancer Therapeutics.

[9]  T. Whiteside Signaling defects in T lymphocytes of patients with malignancy , 1999, Cancer Immunology, Immunotherapy.

[10]  J. Rathmell,et al.  Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.

[11]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[12]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[13]  F. Sarkar,et al.  Microenvironment generated during EGFR targeted killing of pancreatic tumor cells by ATC inhibits myeloid-derived suppressor cells through COX2 and PGE2 dependent pathway , 2013, Journal of Translational Medicine.

[14]  L. O’Neill A broken krebs cycle in macrophages. , 2015, Immunity.

[15]  B. Seliger,et al.  Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8+ T‐cell infiltration in the tumor , 2011, International journal of cancer.

[16]  R A Jungmann,et al.  c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  K. Klotz,et al.  Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity , 2011, Cancer Immunology, Immunotherapy.

[18]  B. Dutrillaux,et al.  Purine and pyrimidine metabolism in human gliomas: relation to chromosomal aberrations. , 1994, British Journal of Cancer.

[19]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[20]  J. Bartek,et al.  Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene , 2013, Oncotarget.

[21]  F. Issa Foxp3 and Toll-Like Receptor Signaling Balance Treg Cell Anabolic Metabolism for Suppression , 2017 .

[22]  T. Gallart,et al.  Role of glutamate on T-cell mediated immunity , 2007, Journal of Neuroimmunology.

[23]  Masaki Kobayashi,et al.  Effect of diclofenac on SLC16A3/MCT4 by the Caco-2 cell line. , 2016, Drug metabolism and pharmacokinetics.

[24]  Erik Sahai,et al.  Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.

[25]  E. Roth,et al.  Influence of glutamine on the phenotype and function of human monocytes. , 1995, Blood.

[26]  T. Eleftheriadis,et al.  Dichloroacetate at therapeutic concentration alters glucose metabolism and induces regulatory T-cell differentiation in alloreactive human lymphocytes , 2013, Journal of basic and clinical physiology and pharmacology.

[27]  W. Gronwald,et al.  New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells , 2013, PloS one.

[28]  Gregory Stephanopoulos,et al.  Metabolic requirements for cancer cell proliferation , 2016, Cancer & metabolism.

[29]  P. Oefner,et al.  Direct and tumor microenvironment mediated influences of 5′‐deoxy‐5′‐(methylthio)adenosine on tumor progression of malignant melanoma , 2009, Journal of cellular biochemistry.

[30]  M. Wolkers,et al.  TLR-Mediated Innate Production of IFN-γ by CD8+ T Cells Is Independent of Glycolysis , 2016, The Journal of Immunology.

[31]  J. C. Aledo,et al.  Phosphate‐activated glutaminase expression during tumor development , 1994, FEBS letters.

[32]  Russell G. Jones,et al.  Stomatin-like Protein 2 Deficiency in T Cells Is Associated with Altered Mitochondrial Respiration and Defective CD4+ T Cell Responses , 2012, The Journal of Immunology.

[33]  Daniel L. Kastner,et al.  Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS) , 2011, The Journal of experimental medicine.

[34]  K. Frauwirth,et al.  Glutamine Uptake and Metabolism Are Coordinately Regulated by ERK/MAPK during T Lymphocyte Activation , 2010, The Journal of Immunology.

[35]  W. Dröge,et al.  Elevated plasma glutamate levels in colorectal carcinoma patients and in patients with acquired immunodeficiency syndrome (AIDS). , 1987, Immunobiology.

[36]  V. De Rosa,et al.  Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants , 2015, Nature Immunology.

[37]  Steffen Hauptmann,et al.  Prognostic impact of cyclooxygenase-2 in breast cancer. , 2004, Clinical breast cancer.

[38]  O. Warburg,et al.  [Metabolism of leukocytes]. , 1958, Zeitschrift fur Naturforschung. Teil B, Chemie, Biochemie, Biophysik, Biologie und verwandte Gebiete.

[39]  G. V. D. Windt,et al.  Metabolic switching and fuel choice during T‐cell differentiation and memory development , 2012, Immunological reviews.

[40]  E. Geissler Post-transplantation malignancies: here today, gone tomorrow? , 2015, Nature Reviews Clinical Oncology.

[41]  A. Bosserhoff,et al.  Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma. , 2006, Carcinogenesis.

[42]  T. Soga Cancer metabolism: Key players in metabolic reprogramming , 2013, Cancer science.

[43]  T. Holowka,et al.  Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. , 2010, Blood.

[44]  F. D’Acquisto,et al.  Lactate Regulates Metabolic and Pro-inflammatory Circuits in Control of T Cell Migration and Effector Functions , 2015, PLoS biology.

[45]  B. Landau,et al.  Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. , 1958, Journal of the National Cancer Institute.

[46]  M. Lai,et al.  A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA , 2009, Clinical Cancer Research.

[47]  Di Chen,et al.  Silencing IDO in dendritic cells: A novel approach to enhance cancer immunotherapy in a murine breast cancer model , 2013, International journal of cancer.

[48]  A. Goldrath,et al.  Constitutive Glycolytic Metabolism Supports CD8+ T Cell Effector Memory Differentiation during Viral Infection. , 2016, Immunity.

[49]  A. Unal,et al.  Adenosine deaminase, 5'-nucleotidase, guanase and cytidine deaminase activities in gastric tissues from patients with gastric cancer. , 1994, Cancer letters.

[50]  A. Halestrap The monocarboxylate transporter family—Structure and functional characterization , 2012, IUBMB Life - A Journal of the International Union of Biochemistry and Molecular Biology.

[51]  R. Çetin,et al.  Activities of adenosine deaminase, 5′-nucleotidase, guanase, and cytidine deaminase enzymes in cancerous and non-cancerous human breast tissues , 2005, Breast Cancer Research and Treatment.

[52]  H. Erdjument-Bromage,et al.  TLR signaling augments macrophage bactericidal activity through mitochondrial ROS , 2011, Nature.

[53]  M. Troester,et al.  Metabolic Reprogramming of Macrophages , 2014, The Journal of Biological Chemistry.

[54]  P. Thevenot,et al.  l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. , 2015, Cancer research.

[55]  U. Grohmann,et al.  The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1 , 2006, The Journal of Immunology.

[56]  O. Warburg,et al.  Stoffwechsel der weißen Blutzellen , 1958 .

[57]  Rodrigue Rossignol,et al.  Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy. , 2015, The international journal of biochemistry & cell biology.

[58]  Linda V. Sinclair,et al.  Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy , 2016, Nature Immunology.

[59]  David S. McClintock,et al.  Role of Oxidants in NF-κB Activation and TNF-α Gene Transcription Induced by Hypoxia and Endotoxin1 , 2000, The Journal of Immunology.

[60]  M. Smyth,et al.  Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs , 2013, Clinical Cancer Research.

[61]  Liang Zheng,et al.  Succinate is an inflammatory signal that induces IL-1β through HIF-1α , 2013, Nature.

[62]  A. Bosserhoff,et al.  Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma. , 2003, The American journal of pathology.

[63]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[64]  G. Semenza,et al.  Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.

[65]  W. Wick,et al.  Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors , 2015, Front. Immunol..

[66]  T. Sparwasser,et al.  Fatty acid metabolism in the regulation of T cell function. , 2015, Trends in immunology.

[67]  G. Koehl,et al.  A Color-Coded Reporter Model to Study the Effect of Immunosuppressants on CD8+ T-Cell Memory in Antitumor and Alloimmune Responses , 2013, Transplantation.

[68]  O. Warburg,et al.  THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.

[69]  E. Newsholme,et al.  Glutamine metabolism in lymphocytes of the rat. , 1983, The Biochemical journal.

[70]  Philippe A. Robert,et al.  Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation , 2015, Science Signaling.

[71]  A. Frey,et al.  Cancer-induced Defective Cytotoxic T Lymphocyte Effector Function: Another Mechanism How Antigenic Tumors Escape Immune-mediated Killing , 2000, Molecular medicine.

[72]  M. Albert,et al.  A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. , 2005, Blood.

[73]  J. Licht,et al.  Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. , 2013, Immunity.

[74]  B. Kuster,et al.  Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity , 2016, Nature Medicine.

[75]  J. Pouysségur,et al.  HIF at a glance , 2009, Journal of Cell Science.

[76]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[77]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[78]  Russell G. Jones,et al.  Enhancing CD8 T-cell memory by modulating fatty acid metabolism , 2009, Nature.

[79]  E. Giovannetti,et al.  Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia , 2013, British Journal of Cancer.

[80]  H. Hoogsteden,et al.  COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function , 2010, BMC Cancer.

[81]  Stefan Schneeberger,et al.  Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[82]  P. Oefner,et al.  Metabolic plasticity of human T cells: Preserved cytokine production under glucose deprivation or mitochondrial restriction, but 2‐deoxy‐glucose affects effector functions , 2015, European journal of immunology.

[83]  M. Battaglia,et al.  Rapamycin Promotes Expansion of Functional CD4+CD25+FOXP3+ Regulatory T Cells of Both Healthy Subjects and Type 1 Diabetic Patients1 , 2006, The Journal of Immunology.

[84]  M. Kreutz,et al.  The Metabolic Achilles Heel: Tumor Cell Metabolism as Therapeutic Target , 2010 .

[85]  D. Cantrell,et al.  Serine-threonine kinases in TCR signaling , 2014, Nature Immunology.

[86]  D. Qualtrough,et al.  Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. , 2006, Cancer research.

[87]  Anita Gandhi,et al.  Immunomodulatory Effects in a Phase II Study of Lenalidomide Combined with Cetuximab in Refractory KRAS-Mutant Metastatic Colorectal Cancer Patients , 2013, PloS one.

[88]  H. Udono,et al.  Immune-mediated antitumor effect by type 2 diabetes drug, metformin , 2015, Proceedings of the National Academy of Sciences.

[89]  N. Chandel,et al.  Role of oxidants in NF-kappa B activation and TNF-alpha gene transcription induced by hypoxia and endotoxin. , 2000, Journal of immunology.

[90]  P. Oefner,et al.  Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis , 2009, Leukemia.

[91]  O. Kretz,et al.  Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming , 2016, Cell.

[92]  E. Pearce,et al.  Immunometabolism governs dendritic cell and macrophage function , 2016, The Journal of experimental medicine.

[93]  I. Biaggioni,et al.  Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells , 2011, The Journal of Immunology.

[94]  T. Gaber,et al.  Effects of hypoxia and/or lack of glucose on cellular energy metabolism and cytokine production in stimulated human CD4+ T lymphocytes. , 2010, Immunology letters.

[95]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[96]  J. Rathmell,et al.  The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. , 2014, Cell metabolism.

[97]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[98]  Qingsheng Li,et al.  The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. , 2010, Immunity.

[99]  D. Wallace,et al.  Essential role of mitochondrial energy metabolism in Foxp3+ T‐regulatory cell function and allograft survival , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[100]  W. Weichert,et al.  Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma , 2004, Clinical Cancer Research.

[101]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[102]  M. Santoro,et al.  Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment. , 2014, The Journal of clinical endocrinology and metabolism.

[103]  P. Oefner,et al.  Suppressive effects of tumor cell-derived 5′-deoxy-5′-methylthioadenosine on human T cells , 2016, Oncoimmunology.

[104]  C. Leslie,et al.  Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism , 2016, Science.

[105]  D. Green,et al.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. , 2011, Immunity.

[106]  B. Faubert,et al.  Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis , 2013, Cell.

[107]  P. Sinha,et al.  Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. , 2010, Cancer research.

[108]  H. Shime,et al.  Tumor-Secreted Lactic Acid Promotes IL-23/IL-17 Proinflammatory Pathway1 , 2008, The Journal of Immunology.

[109]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[110]  E. Shevach,et al.  Foxp3‐mediated inhibition of Akt inhibits Glut1 (glucose transporter 1) expression in human T regulatory cells , 2015, Journal of leukocyte biology.

[111]  E. Rofstad,et al.  High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. , 2000, Cancer research.

[112]  A. Ross,et al.  Monocarboxylate transporter MCT1 is a target for immunosuppression , 2005, Nature chemical biology.

[113]  C. Rock,et al.  T Cells Encountering Myeloid Cells Programmed for Amino Acid-dependent Immunosuppression Use Rictor/mTORC2 Protein for Proliferative Checkpoint Decisions* , 2016, The Journal of Biological Chemistry.

[114]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[115]  M. Mann,et al.  L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity , 2016, Cell.

[116]  L. Oberley,et al.  Discrete Generation of Superoxide and Hydrogen Peroxide by T Cell Receptor Stimulation , 2002, The Journal of experimental medicine.

[117]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[118]  E. Thiel,et al.  Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma. , 2011, European journal of cancer.

[119]  P. Oefner,et al.  Lactic Acid and Acidification Inhibit TNF Secretion and Glycolysis of Human Monocytes , 2009, The Journal of Immunology.

[120]  X. Deng,et al.  Inhibition of mTORC1 signaling sensitizes hepatocellular carcinoma cells to glycolytic stress. , 2016, American journal of cancer research.

[121]  D. Cantrell,et al.  Metabolism, migration and memory in cytotoxic T cells , 2011, Nature Reviews Immunology.

[122]  B Crabtree,et al.  The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells , 1985, Bioscience reports.

[123]  C. Hess,et al.  Rapid effector function of memory CD8+ T cells requires an immediate-early glycolytic switch , 2013, Nature Immunology.

[124]  C. Klemke,et al.  Mitochondrial Reactive Oxygen Species Control T Cell Activation by Regulating IL-2 and IL-4 Expression: Mechanism of Ciprofloxacin-Mediated Immunosuppression , 2010, The Journal of Immunology.

[125]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[126]  H. Kwan,et al.  Involvement of vascular endothelial growth factor (VEGF) in Leydig cell-macrophage interaction of the rat testes , 1998 .

[127]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[128]  S. Haferkamp,et al.  LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. , 2016, Cell metabolism.

[129]  Dudley Lamming,et al.  The TSC-mTOR pathway regulates macrophage polarization , 2013, Nature Communications.

[130]  C. Muñoz-Pinedo,et al.  Regulation of cancer metabolism by oncogenes and tumor suppressors. , 2014, Methods in enzymology.

[131]  I. Müller,et al.  Differential impact of l-arginine deprivation on the activation and effector functions of T cells and macrophages , 2008, Journal of leukocyte biology.

[132]  G. Collins The next generation. , 2006, Scientific American.

[133]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[134]  R. Ahmed,et al.  TOR in the immune system. , 2011, Current opinion in cell biology.

[135]  M. Atkins,et al.  Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. , 2009, Cancer research.

[136]  M. Sitkovsky,et al.  Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. , 1997, Blood.

[137]  Susan R. Quinn,et al.  Pyruvate kinase M2 regulates Hif-1α activity and IL-1β induction and is a critical determinant of the warburg effect in LPS-activated macrophages. , 2015, Cell metabolism.

[138]  A. Mackensen,et al.  Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. , 2006, Blood.

[139]  S. Dubinett,et al.  Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma , 2005, The Journal of experimental medicine.

[140]  J. Locasale,et al.  Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses , 2015, Cell.

[141]  J. Schilling,et al.  Glutamine Modulates Macrophage Lipotoxicity , 2016, Nutrients.

[142]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[143]  A. Viola,et al.  Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers , 2005, The Journal of experimental medicine.

[144]  D. Newton,et al.  Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC , 2010, International journal of cancer.

[145]  Bin Hu,et al.  Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c‐Jun activation , 2012, International journal of cancer.

[146]  J. Rathmell,et al.  Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways1 , 2008, The Journal of Immunology.

[147]  E. Eigenbrodt,et al.  The tumor metabolome. , 2003, Anticancer research.

[148]  W. Evans,et al.  Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. , 2009, Blood.

[149]  David K. Finlay,et al.  mTORC1-Dependent Metabolic Reprogramming Is a Prerequisite for NK Cell Effector Function , 2014, The Journal of Immunology.